Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | CCR3 | P51677 | 3/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602591 | 0.85 | HRH3 (0.71) | DRD2DRD3HRH3SLC6A2SLC6A3 | |
| SCHEMBL4238759 | 0.85 | HRH3 (0.71) | DRD2DRD3HRH3PDE9A | |
| SCHEMBL3608160 | 0.84 | DRD3 (0.59) | DRD2DRD3HRH3SLC6A2SLC6A3 | |
| SCHEMBL19575434 | 0.81 | HRH3 (0.53) | DRD2DRD3HRH3SLC6A2SLC6A3 | |
| SCHEMBL10169414 | 0.80 | HRH3 (0.49) | HRH3SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4237007 | 0.80 | HRH3 (0.48) | HRH3SLC6A2SLC6A3 | |
| SCHEMBL6496199 | 0.78 | SLC6A2 (0.66) | HRH3SLC6A2SLC6A3MGLLSLC6A4 | |
| SCHEMBL26049997 | 0.78 | SLC6A2 (0.66) | DRD2DRD3HRH3SLC6A2SLC6A3 | |
| SCHEMBL4440335 | 0.78 | DRD3 (0.52) | DRD2DRD3HRH3SLC6A2SLC6A3 | |
| SCHEMBL3289104 | 0.78 | HRH3 (0.68) | DRD2DRD3HRH3SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | DRD2 337/4885DRD3 384/4885HRH3 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.